Activating p53 Protein Boosts Engineered T Cells Against Cancer
UCLA researchers use the drug navtemadlin to block MDM2, preventing immune cell exhaustion and improving melanoma destruction in laboratory tests.
By Letizia Giugliano
2 min readHuman-Edited, AI-Assisted
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have found that temporarily activating the tumor-suppressor protein p53 improves the stamina and killing power of engineered immune cells. The study, published in Frontiers in Immunology, demonstrates that dosing human T cells with the investigational drug navtemadlin during laboratory preparation keeps them from exhausting quickly and enhances their ability to destroy melanoma cells.
Blocking MDM2 to reinforce cellular stamina
Engineered cell therapies such as chimeric antigen receptor (CAR) T-cell therapy and T-cell receptor (TCR) therapy modify a patient's own white blood cells to target tumors. A major obstacle in solid tumors is cell exhaustion, where lymphocytes gradually lose their ability to multiply and kill target tissues after repeated exposure to disease. As reported by MedicalXpress, this therapeutic innovation bypasses the need for extra genetic editing by adding a chemical compound during cell preparation.
The research team at the UCLA Health Jonsson Comprehensive Cancer Center focused on p53, a protein known as the guardian of the genome for its role in preventing damaged cells from turning malignant. To test its influence on healthy immune cells, researchers added navtemadlin, an investigational drug that inhibits MDM2, a regulatory protein that normally degrades p53. Inhibiting MDM2 temporarily lifts that brake, allowing p53 levels to rise inside cultured human T cells.
Superior cancer clearing within 40 hours
The researchers genetically engineered human T cells to recognise a specific surface marker on melanoma cells and placed them in co-culture. Using automated imaging systems, they monitored cell interactions continuously for nearly seven days.
T cells treated with navtemadlin developed primarily into central memory T cells, which multiply efficiently and persist over long periods. These lymphocytes retained higher energy reserves and displayed fewer molecular signs of exhaustion. When introduced to melanoma targets, the treated cells began clearing malignant cells more effectively after approximately 40 hours and sustained that advantage throughout the run, as detailed by MedicalXpress. The modified cells released higher amounts of interferon-gamma and granzyme B, two proteins required to destroy tumor cells, without requiring extra doses of interleukin-2.
Dosage precision and manufacturing integration
Controlling the chemical exposure proved essential to keeping the cells viable. At lower concentrations, navtemadlin promoted the formation of memory T cells without reducing total cell counts, whereas excessive concentrations caused cell death. The research team noted that balancing the compound allows existing manufacturing protocols to adopt the method without overhauling genetic engineering vectors.
Because the process relies on an existing drug compound rather than additional genomic insertions, it offers a direct pathway for technology transfer into hospital cleanrooms. Future work will determine whether this laboratory invention can improve persistence in animal models before moving into clinical trials for human solid tumors.
Read also on The Patent: Merck and Moderna mRNA Vaccine Slashes Melanoma Recurrence Risk · Fraunhofer IDMT Develops Wearable trEEGrid Patch for 24-Hour EEG Monitoring
